Please assess the completion status of the following clinical trial:

Trial Title: TevaGastrim for Stem Cell Mobilization Sibling Donors

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Age between 18 and 70 years.~2. Normal sibling donor that is HLA matched to a patient with AML or MDS that needs and is eligible for allogeneic stem cell transplantation~3. Written informed consent.~Exclusion Criteria:~1. Inability to tolerate PBPC harvest.~2. Peripheral venous access not possible.~3. Positive pregnancy test for female donors.~4. Positive serology for hepatitis C and/or HBSAg, unless negative for antigen PCR.~5. Psychiatric, addictive, or any disorder which compromises ability to give truly informed consent for participation in this study.~6. Treatment with other investigational drugs.~7. Known sensitivity to CHO derived products.~8. HIV positive.~9. History of malignant disease or current malignancy.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: t

Study Arms:
- TevaGastrim (Type: EXPERIMENTAL): treatment with TevaGastrim for allogeneic stem cell collection

Based on this trial design, predict the completion outcome and termination type (if applicable).